Date: 2011-09-12
Type of information: Grant
Company: Diamyd Medical (Sweden)
Investors: NIH (USA)
Amount: $3 million (€2.2 million)
Funding type: grant
Planned used: The three-year grant funds the development of a NTDDS-based drug candidate, engineered to deliver a neurotrophic factor to nerve cells. It is hoped that use of NTDDS to deliver such a neurotrophic factor to cancer patients prior to initiating chemotherapy will prevent peripheral neuropathy, which is a common side effect of chemotherapy. Typical symptoms of peripheral neuropathy are numbness, pain, tingling, or burning sensations in hands and feet.
Others: Diamyd Medical has received a three million dollar grant from the US National Institutes of Health to develop the Company\'s patented Nerve Targeting Drug Delivery System (NTDDS) for prevention of Chemotherapy Induced Peripheral Neuropathy. The grant allows Diamyd to expand the NTDDS technology to also target neuropathy, in addition to the Company\'s development portfolio for the treatment of pain.
Therapeutic area: Cancer - Oncology - CNS diseases
